Potential Test-Negative Design Study Bias in Outbreak Settings: Application to Ebola vaccination in Democratic Republic of Congo

Carl A. B. Pearson[1,2,*], W. John Edmunds[1], Thomas J. Hladish[3], Rosalind M. Eggo[1]

[1]Department of Infectious Disease Epidemiology & Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine

[2]South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University

[3]Department of Biology & Emerging Pathogens Institute, University of Florida

*carl.pearson@lshtm.ac.uk

Abstract

Background

Infectious disease outbreaks present unique challenges to study designs for vaccine evaluation. Test-negative design (TND) studies have previously been used to estimate vaccine effectiveness and have been proposed for Ebola virus disease (EVD) vaccines. However, there are key differences in how cases and controls are recruited during outbreaks and pandemics of novel pathogens that have implications for the reliability of effectiveness estimates using this design.

Methods

We use a modelling approach to quantify TND bias for a prophylactic vaccine under varying study and epidemiological scenarios. Our model accounts for heterogeneity in vaccine distribution and for two potential routes to testing and recruitment into the study: self-reporting and contact-tracing. We derive conventional and hybrid TND estimators for this model and suggest ways to translate public health response data into the parameters of the model.

Results

Using a conventional TND study, our model finds biases in vaccine effectiveness estimates. Bias arises due to differential recruitment from self-reporting and contact-tracing, and due to clustering of vaccination. We estimate the degree of bias when recruitment route is not available, and propose a study design to eliminate the bias if recruitment route is recorded.

Conclusions

Hybrid TND studies can resolve the design bias with conventional TND studies applied to outbreak and pandemic response testing data, if those efforts collect individuals' routes to testing. Without route to testing, other epidemiological data will be required to estimate the magnitude of potential bias in a conventional TND study. Since these studies may need to be conducted retrospectively, public health responses should obtain these data, and generic protocols for outbreak and pandemic response studies should emphasize the need to record routes to testing.

Key Messages

- Conventional Test-Negative Design (TND) studies can be biased when follow-up of cases leads to testing and recruitment, which occurs for example during contact tracing.
- A hybrid TND estimator can eliminate this bias, if individual testing routes are recorded.
- The related bias in the conventional TND estimator can be quantified using epidemiological measures.
- If testing route data is unavailable, bias can be limited by other study measures.

Background

Study designs to evaluate new vaccines during outbreaks and pandemics are challenging for logistical, epidemiological, social, and ethical reasons (1-7). Novel and poorly understood pathogens can rapidly overwhelm local health systems, subsequently enabling other crises, or require intensive control policies, complicating both response efforts and research (8-11). However, some key pathogens are only routinely observable under these conditions, like Ebola virus disease (EVD) and others on the World Health Organization (WHO) R&D Blueprint priority list (12).

During outbreaks of highly pathogenic infections there may be pressure to introduce experimental vaccines as quickly as possible (13, 14), as well as resistance to classical randomised controlled trials (15). For EVD, the existence of a licensed vaccine (rVSV-ZEBOV) (16-19) further complicates trials for new vaccines. Such circumstances suggest alternative evaluation strategies, and a test-negative design (TND) study has been proposed to evaluate a two-dose vaccine in eastern Democratic Republic of Congo (DRC) (20-22). This design estimates vaccine effectiveness from the odds ratio for test outcome conditional on vaccination status and has lower misclassification bias than traditional case-control studies (23, 24).

TND studies have been used to estimate the effectiveness of vaccines against influenza (25), rotavirus (26-28), pneumococcus (29), and other pathogens (30, 31). The approach can also assess interventions such as vector control and risk-factor management (32-34). TND studies recruit people with symptoms, test those recruits using a highly sensitive and specific method to separate cases (test-positives) from controls (test-negatives), and finally sort them by vaccination status (35). TND studies can be retrospective, potentially using stratification by other factors to limit confounding effects. For influenza, TND studies usually recruit people seeking care for influenza-like illness, ascertain vaccine status by self-report, and determine infection status by RT-PCR, though specifics vary (25, 30).

To obtain unbiased estimates, the following criteria must be met: i) transmission occurs in a population with partial vaccine coverage; ii) vaccination status does not affect symptom rates unrelated to the target pathogen; iii) given symptoms in an individual, care-seeking behaviour does not vary by underlying cause; iv) an individual's past recruitment as a control (even multiple times) must not prevent subsequent recruitment as a case; and v) there is no misclassification of individuals' infection or vaccine status (33, 36).

Here we examine how outbreaks present novel misclassification problems for TND studies and how this can bias TND vaccine effectiveness estimates, and we quantify how that bias varies with differences in vaccine distribution, recruitment, risk of infection, and testing practice. We introduce a hybrid design that can address these biases, and we identify alternative steps to mitigate potential bias.

Methods

Key Differences During Outbreaks

During outbreaks and pandemics, testing is used both to make treatment decisions for individuals and to trigger public health responses (*e.g.* testing conducted post-mortem or of asymptomatic contacts). For example, during EVD outbreaks, suspect cases may be tested because of i) presence of symptoms or ii) high-risk contact with a known case (37, 38). We represent these testing reasons as distinct recruiting routes: self-reporting people who seek care for EVD-like symptoms (analogous to influenza studies); and people identified via active contact-tracing from a confirmed case (commonly part of public health control efforts during outbreak and pandemic responses). However, depending

90   on how data are collected, we may know total numbers for each testing route, but not matched to
91   outcome. For clarity, we provide specific definitions for our model terms (Table 1).

92   **(Table 1 here).**

Vaccination Model

Vaccinated individuals avoid infection if exposed to EVD with probability E, the true vaccine efficacy.
We assume all-or-nothing vaccine protection. The study measures $\hat{E}$, the estimated vaccine
effectiveness. While there may be a delay from vaccination to protection, *e.g.* a multiple dose
requirement, we model a scenario where protection has already occurred in vaccinated individuals.
Aside from preventing EVD, we assume vaccination has no effect.

We represent vaccine distribution by dividing the recruitable population into two types of
individuals: those targeted by the vaccination campaign and those not (Figure 1), referred to as the
targeted, p_{in}, and non-targeted, 1- p_{in}, fractions (Table 1 and Table 2). Among the targeted
population, only some individuals receive the vaccine, leading to a coverage level, L, in that
population. Because we consider a situation where there is already a licensed, efficacious vaccine,
we assume there is no distribution bias (*e.g.* prioritization of healthcare workers) within the targeted
population. We assume individuals cluster by targeted status, such as might occur if study vaccine
distribution targeted particular villages, so the contacts of self-reporting cases always have the same
target/non-target status as the associated case. Aside from these distinctions, all individuals are
identical.

Ideally, a study would recruit only from targeted populations, but these may not be distinguishable
in practice. Indeed, in reality there may be many distinct populations, for example areas with
different vaccination coverage; we consider just two to focus on the impact of heterogeneity.

TND Recruitment Model

We identify recruits by their testing route, either people who self-report or are contact-traced from
a confirmed case (Table 1 and Figure 1), because we assume these have different criteria for testing
(*i.e.* in our application, the self-reporting criteria are more stringent). In the Supplement, we
generalise these as *primary* and *secondary* recruitment routes. We assume that introduced cases in
the recruitable population are found before any contacts have become symptomatic and therefore
infectious (though they may be infected but not yet symptomatic), consistent with the typical
experience in the rVSV-ZEBOV trial in Guinea and deployment in DRC (17, 39). In those efforts, after
identifying an index case via self-reporting, the response programmes contact-traced around that
individual (an index case) to identify potential exposures (direct contacts) and to identify people for
vaccination (contacts-of-contacts) under the ring protocol. This assumption means that in the model
all self-reported cases result from external introductions, and all contact-traced recruits are only
exposed to a single case.

Consistent with the WHO guidance for EVD outbreak response (38), we assume self-reporting
individuals present with multiple EVD-like symptoms. Both EVD and other causes of EVD-like
symptoms lead to these self-reports, resulting in test-positive and test-negative outcomes,
respectively. Targeted and non-targeted populations are assumed to have equal rates of EVD
exposure, but on average the targeted population has fewer EVD cases due to the vaccine. Other
causes of EVD-like symptoms occur at the same rate in both populations. During an outbreak, rates
of EVD exposure and of other causes of EVD-like symptoms may vary, but our analysis only depends
on a consistent, long-term average relative rate of these processes. As such, we can define

parameters as per self-reported test-positive, and we use the background self-reporting test-
negatives per test-positive rate, *B*, to represent the self-reporting process overall (Table 2).

We also represent testing of traced contacts based on the outbreak response control protocols,
which direct testing based on high-risk interaction and fever (38). However, fever is common in EVD-
prone areas and may be subjectively evaluated, so we assume that this criterion is practically based
on high-risk contact. Thus, the average number of tested contacts is λ, which we assume is the same
irrespective of targeted or vaccination status (Supplement Section S3.3 relaxes this assumption).
These contacts are exposed or not, according to the contact-tracing test-positive rate, R'', which is
reduced within the targeted population by the vaccine.

Translating outbreak metrics to estimate bias

To evaluate a particular study's potential bias, we need real-world outbreak response metrics to
estimate model parameters. For studies augmenting an ongoing outbreak response, data already
collected could be used. For example, partial data on the number of tested individuals, stratified by
test outcome and testing route could be used to bound model parameters (Table 2).

The model also depends on how the study vaccination is distributed, represented by targeted
fraction and coverage within that fraction, p_{in} and *L* (respectively). Depending on the study protocol,
these could be ascertained in different ways (Supplement Section S7).

Summary of assumptions

• The study period and population are sufficient to use expected values and minimize the
impact of heterogeneity, for example superspreading events.
• Cases and their contacts have the same targeted status.
• All individuals have the same exposure risk to EVD and other causes of EVD-like symptoms,
average number of contacts, and risk of infection per contact.
• Non-vaccination among targeted populations happens randomly.
• There are different testing criteria for self-reporting and contact-tracing individuals.
• Self-reporting cases are identified before anyone they have infected becomes symptomatic,
and contact tracing prevents transmission among contacts.

(Table 2 here)

TND Estimator for Outbreak Context

162   There are twelve recruitment categories in our model, based on targeted and vaccination status (N,
163   U, and V for non-target, unvaccinated, and vaccinated respectively), test outcome (subscripts – and
164   +), and testing route (annotations ' and '' for self-reporting and contact-tracing respectively) (Table 1
165   and Figure 1). The conventional TND estimator:

$$\frac{\text{estimated}}{\text{effectiveness}} = 1 - \frac{\text{\# vaccinated, test-positive}}{\text{\# unvaccinated, test-positive}} \times \frac{\text{\# unvaccinated, test-negative}}{\text{\# vaccinated, test-negative}}$$

can be written with these categories as:

$\hat{E} = 1 - \frac{V'_+ + V''_+}{N'_+ + N''_+ + U'_+ + U''_+} \times \frac{N'_- + N''_- + U'_- + U''_-}{V'_- + V''_-}$ 　　　　　　　　　(1)

The expected counts of these categories can be expressed with the six model parameters we
defined (full derivation in Supplement S3-S4). Recall these are true efficacy (*E*), the targeted fraction
of the recruitable population (p_{in}), the vaccine coverage in targeted population (*L*), the number of
self-reporting test-negatives per test-positive (*B*), average number of contacts tested per self-

reporting test-positive (λ), and average number of contacts that test-positive (R''). Substituting
these, we can obtain:

174
$$\hat{E} = 1 - (1-E)\left[1+\frac{ER''}{1+R''(1-LE)}\frac{L(1-p_{in})}{1-Lp_{in}}\right]^{-1}\frac{B+\left[1+\frac{Lp_{in}}{1-Lp_{in}}\frac{LE(1-p_{in})}{1-LEp_{in}}\right](\lambda-R'')}{B+\frac{1-LE}{1-LEp_{in}}(\lambda-R''(1-E))} \tag{2}$$

The terms to the right only cancel under very specific circumstances, thus the bias is generally non-
zero and the magnitude is a function of all model parameters. We refactor Eq. (2) with alternative
parameters relating to recruitment and epidemiological measures from the outbreak, namely the
fraction of tests that are negative for self-reporting individuals (f_-), the ratio of contact-traced to
self-reporting individuals (ρ), and the fraction of tests that are positive among contact-traced
individuals in the absence of vaccination (p_t) (Supplement Section S4). We use this form to explore
the bias and to evaluate potential maximum bias under specific outbreak scenarios:

182
$$\hat{E} = 1 - (1-E)\left[1+\frac{E\frac{p_t\rho}{1-f_-}}{1+\frac{p_t\rho}{1-f_-}(1-LE)}\frac{L(1-p_{in})}{1-Lp_{in}}\right]^{-1}\frac{1+\left[1+\frac{Lp_{in}}{1-Lp_{in}}\frac{LE(1-p_{in})}{1-LEp_{in}}\right]\frac{\rho}{f_-}(1-p_t)}{1+\frac{1-LE}{1-LEp_{in}}\frac{\rho}{f_-}(1-p_t(1-E))} \tag{3}$$

183 We also consider an alternative study design, where testing route is always available. In this design,
184 we combine the conventional TND estimator with a conventional cohort study estimator. We
185 evaluate the self-reporting individuals with the TND component and the contact-traced individuals
186 with cohort estimator:

187
$$\hat{E} = \frac{1}{\sum \omega}\left[\omega_{TND}\hat{E}_{TND} + \omega_{CS}\hat{E}_{CS}\right] \tag{4}$$

TND Estimator Bias

Across a wide range of self-reporting test-negative fractions (f_-), contact-tracing test-positive
fractions (p_t), targeted fractions (p_{in}), and testing route ratios (ρ), the absolute error in $\hat{E}$ is ≤ 0.1
(Figure 3). If information from the outbreak response indicates these parameter values are
bounding, then our model indicates conventional study bias lies in that range. Ideally, individual
testing routes will be available, and the hybrid design can be used. When the hybrid design cannot
be used, we have identified two avenues to limit bias, restricting recruitment to either targeted or
self-reporting individuals only.

Hybrid Design: No Recruitment Bias

197 If study data permit stratifying recruits by testing route, then an alternative study design can be used
198 to eliminate the design bias (Figure 2). Consider a cohort study-like estimator of vaccine
199 effectiveness using only the contact-traced recruits:

$$\hat{E}'' = 1 - \frac{V_+''}{V''}\frac{N''+U''}{N_+''+U_+''}$$

Under our model assumptions, this estimator is asymptotically equal to the true efficacy, E. The
positive fraction of contact-traced individuals will be a context specific transmission probability. For
vaccinees, it is reduced by $(1-E)$. The transmission-related term cancels from the two fractions,
leaving only $\hat{E} = 1 - (1-E) = E$, indicating this estimator is asymptotically unbiased. When only
considering self-reporting individuals, our model assumptions match the TND requirements for an
unbiased estimate, and therefore the test-negative estimator limited to self-reporting individuals is
also asymptotically unbiased. Thus, any weighted combination of the two estimators like Eq. (4) is
also asymptotically unbiased.

Restricting Recruitment to Targeted Populations

Ideally, a study would strictly recruit from populations that were targeted for vaccination. This could be achieved either by expanding the targeted (for vaccination) population to coincide with the potentially recruitable (by testing) population, or by censoring the tested population to only the population targeted for vaccination. The former may be possible with, for example, an extensive community engagement programme that results in homogenous coverage across a wide region. The latter may be possible if there is additional data collected, like place of residence, that allows exclusion of individuals outside the targeted population. Even if the study is constrained to only a targeted population, *i.e.* $p_{in} = 1$, some bias remains due to recruitment of contact-traced individuals, but it no longer depends on the vaccine coverage (see Supplement Section S5.1). However, uniformly distributing a vaccine among the population will be complicated in an outbreak response setting, and the bias is sensitive to other factors even when most of the recruited population was targeted (Figure 4).

If the targeted fraction decreases, generally the magnitude of bias in the estimate increases. Bias generally peaks when the true vaccine efficacy is around 50% and goes to zero as true efficacy approaches 0 or 100%. Because initial cases are more likely among non-targeted populations, contact-traced individuals are likewise biased towards being non-targeted and thus un-vaccinated. Thus, bias tends towards overestimation as contact-traced individuals more frequently test positive. This can reverse for high levels of contact-traced recruitment, when most contact-traced individuals are test-negative. All other factors being equal, more coverage means more extreme bias as targeted and non-targeted populations diverge.

Restricting Recruitment to Self-Reported individuals

The bias can also be corrected by restricting recruitment strictly to self-reported individuals. If perfectly achieved, then the bias is 0 (see Supplement S4.4). During outbreak response, priorities and data processes, however, may focus on identified cases, neglecting detailed tracking of test-negatives. Thus, in retrospective analyses, test-negative data might only reflect vaccine status, not route to testing, while more detailed data for test-positives is available. If that applies, the resulting estimator bias is:

$$E - \hat{E} = -(1-E)E\left[\frac{(1-LE)R'' - L\frac{1-p_{\text{in}}}{1-Lp_{\text{in}}}(\lambda - R'')}{B(1-LEp_{\text{in}}) + (1-LE)(\lambda - R''(1-E))}\right] \tag{5}$$

Minimising, and ultimately eliminating, bias in Eq. (5) still depends on maximising p_{in}. One way of achieving high p_{in} is excluding non-targeted populations. This suggests a trade-off between precision and bias: if the study invests the effort to exclude any non-targeted population it may make sense to include contact-traced recruits.

If contact-traced test-positives are excluded retrospectively, the resulting bias magnitude may be lower even if contact-traced test-negatives are included due to misclassification (Figure 4 vs Figure 5). However, the direction of bias changes with changing targeted fraction (p_{in}): the no-bias line falls at higher contact-tracing test-positive fractions (p_t) when targeted fraction decreases. The magnitude of bias at the extremes of the contact-tracing test-positive fractions is driven largely by the number of self-reporting test-negatives. Other factors being equal, fewer self-reported test-negatives means a lower self-reporting test-negative fraction ($f_- = 0.8$ versus 0.99) and higher testing route ratio ($\rho = 0.3$ versus 0.1), both of which correspond to more extreme bias.

Quantifying Potential Bias from Outbreak Response Metrics

To quantify the bias range for an EVD vaccine study in DRC, we determined the plausible range of outbreak response metrics and corresponding model parameters (Table 2). We consider test positive counts SR_+ in (100, 150) and CT_+ in (100, 400), for self-reporting and contact-tracing respectively. We consider test negative counts SR_- in (6500, 7000) and CT_- in (900, 1200), for self-reporting and contact-tracing respectively.

When restricting recruitment to targeted populations only, the bias in estimated effectiveness is less than 3% overestimation (Figure 6, left panel), but can increase to >15% overestimate if coverage is high and targeted fraction is low (Figure 6, right panel; 90% coverage, 40% targeted fraction). As a larger non-targeted population is recruited, increasing coverage increases bias, corresponding to the increasing distinction in infection risk between targeted and non-targeted populations. For these outbreak response metrics, the estimate of vaccine effectiveness consistently exceeds the true efficacy.

When restricting recruitment to self-reported individuals only, with no misclassification of testing route for test-negatives, there is no bias (Figure 7, left panel). As the misclassification increases from 0 to 100%, the magnitude of bias increases and tends towards underestimation, though the range of possible bias includes overestimation. For the most extreme case, where all contact-traced test-negatives are included in a scenario with a low targeted fraction and high coverage, the bias spans roughly 1% overestimate to 5% underestimate (Figure 7, right panel; 90% coverage, 40% targeted fraction). As with restricting recruitment to the targeted population, the magnitude of the bias increases with coverage among targeted individuals.

Discussion

Previous work has explored biases in TND studies due to care-seeking or other confounding and selection effects (35, 40, 41), test or vaccine status misclassification errors (25, 42-44), and vaccine mechanism (36, 45). Here, we demonstrate that public health response efforts can also generate bias in the effectiveness estimates of a conventional TND study. If the response effort collects data on route to testing, a hybrid design study is possible and does not suffer this bias. Retaining this information should therefore be a high priority. This hybrid design warrants further analysis, as we have only considered it with a simplified model.

When a conventional TND study cannot distinguish self-reported and contact-traced recruits, or whether recruits were generally among a population targeted for vaccination, then the vaccine effectiveness estimate is potentially biased. These are both real, practical problems: in addition to general difficulty of collecting data during an outbreak, it may be difficult to achieve uniform levels of coverage when deploying a vaccine in an emergency setting, particularly in highly mobile populations or those affected by civil unrest.

In our model, the bias arises from the interaction of heterogeneous vaccination distribution and the inclusion of tested individuals from contact-tracing. Because initial cases found through self-reporting are more likely to be non-targeted (and thus unvaccinated) individuals, including contact-traced recruits overrepresents those individuals in the estimator. This in turn can tilt the bias either towards or away from the null, depending on how infection risk and testing criteria differ in the contact-traced population versus the general population. If the self-reporting process leads to many more test-negative recruits than recruits from contact-tracing (either positive or negative), then the bias from contact-tracing is relatively smaller. If it does not, then the relative number of cases versus controls from contact-tracing will determine the general direction of bias: more cases lead to overestimation, more controls lead to underestimation.

While the ideal solution is to maintain data on route to testing, if that does not occur we show that
the range of potential bias can be quantified with aggregate epidemiological data from an outbreak.
For the range of outbreak response metrics we used to represent the EVD outbreak in DRC, this is
less than 10% if the study can achieve high targeted fraction ($p_{in} \geq 0.6$) with at most moderate
coverage ($L \leq 0.7$).

Practically, it may be possible to limit but not eliminate these drivers of the bias. For the EVD
epidemic in eastern DRC, responders tried to test individuals meeting one of the outbreak
"suspected case" definitions, which combine different levels of symptoms and potential contact with
known cases (37, 38). This practice would likely continue in populations that received a study
vaccine, meaning this testing process would be the likely source for a retrospective TND study of a
new vaccine.

We framed our analysis in terms of event counts, but it can also be thought of in terms of testing
thresholds. For example, we frame contact-tracing recruitment as a number of contacts and the
number of cases among them. The resulting effectiveness estimator error is then driven by the ratio
of those values. In an infectious disease sense, this ratio is the transmission probability, but it could
instead be interpreted in terms of the sensitivity of the criteria for testing: should testing criteria be
stricter to conserve limited resources, or more relaxed to ensure no positives are missed? A similar
analogy applies for testing self-reporting individuals. For both self-reported and contact-traced
testing, bias in the vaccine effectiveness estimate is generally lower when testing criteria are less
strict (i.e. the protocol is more sensitive), consistent with a control-oriented outbreak response,
while a more resource-limited response would have higher bias.

Our analysis describes vaccination during EVD outbreaks, but our work has general implications for
evaluating interventions in other infectious disease settings with a public health response that
includes testing, for example efforts to control the COVID-19 pandemic. We have focused on self-
reporting and contact-tracing, but the challenges are generic when there are distinct, but potentially
undistinguished, primary and secondary recruiting processes. For example, more active general-
population surveillance could still qualify as the primary recruitment in our model, as long as it were
random with respect to intervention status. Likewise, geographic follow-up could be a secondary
process, as long as intervention status were correlated with the secondary process (*e.g.* for dengue,
adjacent households followed up, as long as vector control reached some areas and not others).

This analysis of the conventional TND and hybrid design under outbreak conditions does not
consider other possible sources of bias, such as different exposure risk between groups, testing
errors, or errors in ascertaining vaccine status. Further investigation of the reliability of these studies
for estimating effectiveness during outbreaks remains critical. However, as we have shown, use of
this design in an outbreak setting will need to account for the realities of control activities and plan
to collect data on testing route or otherwise accommodate the mix of recruitment routes.

Adoption of a TND or hybrid design to evaluate a new vaccine in DRC may increase pressure for
similar studies that do not have an explicit, randomised control group in future outbreaks of similarly
highly pathogenic diseases. Understanding the biases and limitations of these designs will therefore
be critical to evaluate vaccines that are currently being developed against these pathogens.

Acknowledgements
We thank Peter G. Smith and Nick Jewell for useful discussions during the development of this
model and analysis.

This work was supported by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking between
European Union Horizon 2020 Research and Innovation Programme and the European Federation of
Pharmaceutical Industries and Associations [EBOVAC3: grant number 800176]; Department of
Health and Social Care using UK Aid funding managed by the NIHR [VEEPED: PR-OD-1017-20007];
National Institutes of Health, National Institute of General Medical Sciences [U54 GM111274]; and
HDR UK Innovation Fellowship [grant MR/S003975/1 to R.M.E.]. The views expressed in this
publication are those of the authors and not necessarily those of the Department of Health and
Social Care.

References

1.   Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations for
designing and interpreting intervention trials in infectious diseases. BMC Med. 2017;15(1):223.
2.   Bellan SE, Eggo RM, Gsell P-S, Kucharski AJ, Dean NE, Donohue R, et al. An online decision
tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine.
2019;37(31):4376 - 81.
3.   Dean NE, Gsell P-S, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, et al.
Considerations for the design of vaccine efficacy trials during public health emergencies. bioRxiv.
2018.
4.   Baden LR, Rubin EJ, Morrissey S, Farrar JJ, Drazen JM. We Can Do Better - Improving
Outcomes in the Midst of an Emergency. N Engl J Med. 2017;377(15):1482-4.
5.   WHO. Vaccination in acute humanitarian emergencies: a framework for decision making.
2017.
6.   Moodley K, Hardie K, Selgelid MJ, Waldman RJ, Strebel P, Rees H, et al. Ethical
considerations for vaccination programmes in acute humanitarian emergencies. Bull World Health
Organ. 2013;91(4):290-7.
7.   Hatchett R, Lurie N. Outbreak response as an essential component of vaccine development.
The Lancet Infectious Diseases. 2019;19(11):e399-e403.
8.   Owada K, Eckmanns T, Kamara KB, Olu OO. Epidemiological Data Management during an
Outbreak of Ebola Virus Disease: Key Issues and Observations from Sierra Leone. Front Public Health.
2016;4:163.
9.   Kieny MP, Salama P. WHO R&D Blueprint: a global coordination mechanism for R&D
preparedness. The Lancet. 2017;389(10088):2469 - 70.
10.   Hofman M, Au S. The politics of fear: Medecins sans frontieres and the West African Ebola
epidemic: Oxford University Press; 2017.
11.   Beavogui AH, Delamou A, Yansane ML, Konde MK, Diallo AA, Aboulhab J, et al. Clinical
research during the Ebola virus disease outbreak in Guinea: Lessons learned and ways forward. Clin
Trials. 2016;13(1):73-8.
12.   Mehand MS, Al-Shorbaji F, Millett P, Murgue B. The WHO R&D Blueprint: 2018 review of
emerging infectious diseases requiring urgent research and development efforts. Antiviral Res.
2018;159:63-7.
13.   Kupferschmidt K. Plan to use second Ebola vaccine sparks debate. Science.
2019;364(6447):1221-.
14.   Independent Ebola vaccination committee is needed to overcome lack of WHO transparency
[press release]. Medecins Sans Frontieres, 23-09-2019.
15.   Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy J-F, et al. Randomised
controlled trials for Ebola: practical and ethical issues. The Lancet. 2014;384(9952):1423-4.
16.   Consortium EçSRVT. The ring vaccination trial: a novel cluster randomised controlled trial
design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to
Ebola. BMJ (Clinical research ed). 2015;351:h3740.

17.   Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al.
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results
from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet.
2017;389(10068):505 - 18.
18.   Vaccine against Ebola: Commission grants first-ever market authorisation [press release].
European Commission, 11 November 2019.
19.   First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical
milestone in public health preparedness and response [press release]. FDA, 19 December 2019.
20.   WHO. Weekly epidemiological record. World Health Organization; 2019. p. 261–80.
21.   SAGE. Strategic Advisory Group of Experts (SAGE) on Immunization Interim
Recommendations on Vaccination against Ebola Virus Disease (EVD). World Health Organization
(WHO); 2019.
22.   Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen's
Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo
(DRC) [press release]. 2019.
23.   Vandebosch A, Mogg R, Goeyvaerts N, Truyers C, Greenwood B, Watson-Jones D, et al.
Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus
disease infection: Statistical considerations, design rationale, and challenges. Clin Trials.
2016;13(1):57-65.
24.   ECBS ECOBS. Guidelines on the quality, safety and efficacy of Ebola vaccines. WHO Technical
Report Series. 2017;68:87-179.
25.   Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza
vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91.
26.   Araki K, Hara M, Shimanoe C, Nishida Y, Matsuo M, Tanaka K. Case-Control Study of
Rotavirus Vaccine Effectiveness Compared to Test-Negative Controls or Hospital Controls. J
Epidemiol. 2019;29(8):282-7.
27.   Walker JL, Andrews NJ, Atchison CJ, Collins S, Allen DJ, Ramsay ME, et al. Effectiveness of
oral rotavirus vaccination in England against rotavirus-confirmed and all-cause acute gastroenteritis.
Vaccine X. 2019;1:100005.
28.   Haber M, Lopman BA, Tate JE, Shi M, Parashar UD. A comparison of the test-negative and
traditional case-control study designs with respect to the bias of estimates of rotavirus vaccine
effectiveness. Vaccine. 2018;36(33):5071-6.
29.   Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination:
an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med.
1980;303(10):549-52.
30.   Chua H, Feng S, Lewnard JA, Sullivan SG, Blyth CC, Lipsitch M, et al. The use of test-negative
controls to monitor vaccine effectiveness: a systematic review of methodology. Epidemiology. 2019.
31.   Li Y, Zhou Y, Cheng Y, Wu P, Zhou C, Cui P, et al. Effectiveness of EV-A71 vaccination in
prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection
requiring hospitalisation in Henan, China, 2017–18: a test-negative case-control study. The Lancet
Child & Adolescent Health. 2019;3(10):697-704.
32.   Yung CF, Chan SP, Thein TL, Chai SC, Leo YS. Epidemiological risk factors for adult dengue in
Singapore: an 8-year nested test negative case control study. BMC Infect Dis. 2016;16:323.
33.   Anders KL, Cutcher Z, Kleinschmidt I, Donnelly CA, Ferguson NM, Indriani C, et al. Cluster-
Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of
Community-Level Dengue Interventions. Am J Epidemiol. 2018;187(9):2021-8.
34.   Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. The AWED trial
(Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected mosquito
deployments to reduce dengue incidence in Yogyakarta, Indonesia: study protocol for a cluster
randomised controlled trial. Trials. 2018;19(1):302.

35.   Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the
effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104-9.
36.   Dean NE. RE: "MEASUREMENT OF VACCINE DIRECT EFFECTS UNDER THE TEST-NEGATIVE
DESIGN". American Journal of Epidemiology. 2019;188(4):806–10.
37.   WHO. Case definition recommendations for Ebola or Marburg virus diseases. WHO; 2014.
38.   WHO. Implementation and management of contact tracing for Ebola virus disease. WHO;
2015.
39.   WHO. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring
vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an
example of integration of research into epidemic response. 2019.
40.   Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine
effectiveness from test-negative studies. Vaccine. 2017;35(52):7297-301.
41.   Ferdinands JM, Foppa IM, Fry AM, Flannery BL, Belongia EA, Jackson ML. Re: "Invited
Commentary: Beware the Test-Negative Design". Am J Epidemiol. 2017;185(7):613.
42.   Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic
issues regarding the use of three observational study designs to assess influenza vaccine
effectiveness. Int J Epidemiol. 2007;36(3):623-31.
43.   Jackson ML, Rothman KJ. Effects of imperfect test sensitivity and specificity on observational
studies of influenza vaccine effectiveness. Vaccine. 2015;33(11):1313-6.
44.   De Smedt T, Merrall E, Macina D, Perez-Vilar S, Andrews N, Bollaerts K. Bias due to
differential and non-differential disease- and exposure misclassification in studies of vaccine
effectiveness. PLoS One. 2018;13(6):e0199180.
45.   Lewnard JA, Tedijanto C, Cowling BJ, Lipsitch M. Measurement of Vaccine Direct Effects
Under the Test-Negative Design. American Journal of Epidemiology. 2018;187(12):2686–97.

Tables

Table 1: Definitions of terms used in this analysis.

Term	Definition
Recruitable population	The total population who may later be *recruited* into the *study.* In practice, unknown when the *vaccination campaign* occurs, but known in the model.
Vaccination campaign	Administration of the *study vaccine* to some of the *recruitable population.*
Study	A TND study of the *study vaccine* against EVD in the *recruitable population.*
Targeted	The portion of the *recruitable population* who could be vaccinated, with vaccination homogeneously distributed. *Non-targeted* refers to the complementary portion of the *recruitable population*: none of these individuals receive the vaccine.
Recruitment	Testing for potential EVD infection and being counted in the *study*; distinct from being *targeted* (for *vaccination*). Occurs via two routes: *self-reporting* and *contact-tracing.*
Self-reporting (SR)	Testing of individuals without a known link to a previous case.
Contact-tracing (CT)	Testing of individuals because of contact with a confirmed EVD case.
N, U, and V	Populations for non-targeted (N), or targeted and unvaccinated (U) or vaccinated (V).
Annotation ' and "	Recruitment route indicators; e.g. V' would be vaccinated individuals recruited via self-reporting vs N" would be non-targeted individuals recruited via contact-tracing.
Subscript + and -	Test outcome indicators; e.g. U'_- would be unvaccinated individuals, recruited via self-reporting, that test negative vs V''_+ would be vaccinated individuals, recruited via contact-tracing, that test positive.

461
462

463 **Table 2: Parameter Summary.** This table summarizes the measurements and model parameters used in this
464 analysis. We also introduce an alternative parameterization of the recruitment model, which is less intuitive
465 when describing the model but more useful for understanding the impact on bias.

Vaccination Parameters			
Symbol	Name	Description	Calculation
E	True vaccine efficacy	The probability of preventing disease given an EVD exposure	Estimation target
$\hat{E}$	Estimated vaccine effectiveness		Estimator, Equations 1-3
p_{in}	targeted fraction	The fraction of the recruitable population with some vaccine coverage; the *non-targeted fraction*, 1-p_{in}, has no vaccine coverage	*see Supplement Section S7*
L	vaccine coverage	In the targeted population, the achieved vaccine coverage	*see Supplement Section S7*
Outbreak Response Metrics			
SR_+	Self-reported test-positive	Total number of individuals who test positive when they self-report to a health centre	Estimated from outbreak response metrics if available, either before or after start of vaccine campaign
SR_-	Self-reported test-negative	Number who test negative when they self-report to a health centre	
CT_+	Contact-traced test-positive	Number who test positive after identification by contact-tracing from a known case	
CT_-	Contact-traced test-negative	Number who test negative after identification by contact-tracing from a known case	
Recruitment Parameters			
B	Self-reporting test-negative rate	The expected number of self-reporting test-negatives per self-reporting test-positive case	$\dfrac{SR_-}{SR_+}$
λ	Contact-tracing test rate	The expected number of tested contacts per self-reporting test-positive case	$\dfrac{CT_+ + CT_-}{SR_+}$
R''	Contact-tracing test-positive rate	The expected number of new infections among tested contacts of a known case, when the study vaccine is not present, per self-reporting test-positive case	$\dfrac{CT_+}{SR_+}$
Alternative Recruitment Parameters			
f_-	Self-reporting test-negative fraction	The proportion of self-reporting individuals that test-negative	$\dfrac{B}{B+1}$ or $\dfrac{SR_-}{SR_+ + SR_-}$
ρ	Recruitment route ratio	The ratio of contact-tracing recruitment to self-reporting recruitment	$\dfrac{\lambda}{B+1}$ or $\dfrac{CT_+ + CT_-}{SR_+ + SR_-}$
p_t	Contact-tracing test-positive fraction	The test-positive fraction of direct contact-tracing recruitment in the absence of vaccination	$\dfrac{R''}{\lambda}$ or $\dfrac{CT_+}{CT_+ + CT_-}$

Figures

Figure 1. The modelled population and recruitment into the TND study. (a) Individuals and their contacts are either targeted for vaccination (filled circles – dark blue receive the vaccine and light blue do not) or not (open circles). (b) The fraction that are targeted (and thus may be vaccinated) is p_{in}; none of the non-targeted population (open circles, N label) receives the vaccine. Of those targeted, some are not vaccinated (e.g. because they are ineligible due to age, pregnancy, recent illness, immunocompromised status; or because there is only sufficient study vaccine to deliver partial coverage) (light blue, U label) and some are (dark blue, V label). The vaccine coverage in the targeted population is L. In the recruitable population (the combination of N, U, and V), non-vaccinees (N and U) are infected on EVD exposure, while vaccines (V) avoid disease at the vaccine efficacy, E. (c) An expected number of self-reported people test negative (circles with – sign), B, until a test-positive (circle with + sign) is identified. This leads to an expected amount of follow-up testing, λ, which finds R" more cases if the initial case is in the non-targeted population, and (1-LE)R" if targeted. The coverage, L, efficacy, E, and targeted fraction, p_{in}, determine the likelihood of observing the self-reporting case among targeted vs non-targeted individuals and vaccinated vs unvaccinated individuals. (d) Resulting categories that can be recruited into the study. U and V are, respectively, the unvaccinated and vaccinated individuals in the targeted population; N are non-targeted individuals. The ' vs " annotations indicate, respectively, self-reporting vs contact-traced, and the – vs + subscripts indicate test-negative and test-positive outcomes, respectively.

Figure 2. Recruitment into Hybrid Study. An alternative study design combining the test-negative estimator for self-reporting individuals and a cohort-study style estimator for contact-traced individuals. This arrangement eliminates the design bias identified for the conventional TND but requires that individuals be stratified by recruitment route.

Figure 3: Bias Trends Across All Model Parameters. The figure illustrates the bias trends with respect to true efficacy, *E*, and vaccination coverage in the targeted population, *L*. The sixteen panels correspond to combinations of example values for: (outer columns) self-reporting test-negative fraction (at low = 0.8 and high = 0.99); (inner columns) the recruitment route ratio (ρ at low = 0.5 and high = 2; less than 1 implies more self-reporting recruitment, greater than 1 implies more contact-tracing recruitment); (outer rows) contact-tracing test-positive fraction (at low = 0.1 and high = 0.3); and the targeted fraction (p_{in}, at low = 0.6 and high = 0.9).

Figure 4: Impact of Decreasing Targeted Fraction Among Recruits. The panels show decreasing targeted fraction (columns from left to right) for scenarios stratified by self-reported test-negative fraction in recruitment (0.8 and 0.99) and recruitment route ratio (0.1 and 0.3) (rows). This figure shows 70% coverage level in the targeted population, L=0.7.

Figure 5: Bias Due to Inability to Exclude Contact-Traced Test-Negatives. The panels show decreasing
targeted fraction (columns from left to right) for scenarios stratified by self-reported test-negative fraction in
recruitment (0.8 and 0.99) and recruitment route ratio (0.1 and 0.3) (rows). This figure shows 70% coverage
level among targeted individuals, *L*=0.7. The range of bias is usually smaller than when recruitment is
restricted to the targeted population only (Figure 4).

Figure 6: Bias possible when recruiting targeted individuals only. These bias envelopes were computed
assuming outbreak response metrics   ,   ,   , and
                          , which corresponds to 97.7-98.6% of self-reporting cases testing negative, testing 6-16
contact-traced individuals per self-reported case, and 10-25% of those contact-traced individuals testing
positive. If the study is restricted to recruit only the targeted population (left-most panel), then bias can be
limited to less than 3% overestimation. However, as the targeted fraction falls, the error range generally
increases, to >15% peak bias for high coverage (90%) and low targeted fraction (40%). Higher coverage in the
targeted population generally increases bias; this reflects increasing differences between the targeted and
non-targeted individuals.

Figure 7: Bias possible when recruitment is restricted to self-reported individuals only. If the study analysis is
able to restrict recruits to only self-reporting individuals, then there is no bias (left panel). However, as
contact-traced test-negative individuals are increasingly included (moving right across panels), bias range
increases to between 1% overestimate and 5% underestimate. However, this range is notably smaller than if
only recruiting from the targeted population (Figure 6). As with restricting recruitment to targeted individuals
only, higher levels of coverage lead to wider bias range. These ranges reflect the same parameters used in
Figure 6, including targeted fraction   . In this figure, the overestimate bounds (upper ribbon lines)
closely align.